General Announcement::Press Release - Launch of Sublingual Dexmedetomidine Programme
Issuer & Securities
Issuer/ Manager
IX BIOPHARMA LTD.
Securities
IX BIOPHARMA LTD. - SG1BD9000009 - 42C
Stapled Security
No
Announcement Details
Announcement Title
General Announcement
Date &Time of Broadcast
29-Aug-2022 07:33:18
Status
New
Announcement Sub Title
Press Release - Launch of Sublingual Dexmedetomidine Programme
Announcement Reference
SG220829OTHRPR03
Submitted By (Co./ Ind. Name)
Gwendolin Lee
Designation
Company Secretary
Description (Please provide a detailed description of the event in the box below)
Please see attached.
This announcement has been prepared by the Company and its contents have been reviewed by the Company s sponsor, UOB Kay Hian Private Limited (the "Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.
This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.
The contact person for the Sponsor is Mr Lance Tan, Senior Vice President at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.
Attachments
Press Release - Sublingual Dexmedetomidine Programme 290822.pdf
Total size =95K
Related Announcements
Related Announcements